Bayer’s proposed $7.25 billion nationwide class settlement over Roundup — filed as King v. Monsanto in Missouri state court — is facing a wave of formal objections, and the most contentious issue is its attempt to bind people who have not yet developed cancer. The deal, which covers non-Hodgkin lymphoma claims tied to Roundup’s active ingredient glyphosate, includes a “futures” subclass that would sweep in users who are currently healthy but may be diagnosed years from now. Critics argue the structure could even bind people “not yet conceived,” and more than 100 class members, roughly a dozen health care plans, and prominent plaintiffs’ firms have told the court the arrangement is fundamentally unfair.
The objections are not abstract legal quibbles. On May 21 and 22, 2026, Keller Postman LLC, led by Ashley C. Keller, and Frazer PLC filed objections on behalf of 10 Roundup victims from nine states, calling the settlement a “sweetheart deal” that violates constitutional due process and is “comically difficult” to opt out of. Meanwhile, the settlement’s funding schedule stretches roughly 17 to 21 years, and caps would allocate about $40,000 to residential users — figures that objecting victims have called “unconscionably low.” With the final fairness hearing pushed from July 9 to August 19, 2026, final approval remains an open question.
Table of Contents
- Why Does the Bayer Roundup Settlement Cover Future Cancer Claims?
- What the Objectors Say Is Wrong With the Deal
- The Jurisdictional Fight — Why This Case Bounced Between Courts
- What Class Members Can Do — Opting Out Versus Staying In
- The Futures Problem — Why Courts Have Struck Down Deals Like This Before
- The $675 Million Attorney Fee Request
- Where the Glyphosate Litigation Stands Beyond This Settlement
- Frequently Asked Questions
Why Does the Bayer Roundup Settlement Cover Future Cancer Claims?
The core of Bayer’s strategy is finality. The company has spent years litigating tens of thousands of claims alleging that glyphosate-based Roundup causes non-Hodgkin lymphoma, and individual verdicts have repeatedly gone against it. A conventional settlement resolves only the claims of people who have already been diagnosed and signed on. The King v. Monsanto structure goes further: by certifying a “futures” subclass, it would extinguish or channel the claims of Roundup users who develop cancer in the years or decades ahead, in exchange for a funding schedule that stretches roughly 17 to 21 years.
For Bayer, that trade makes obvious business sense — non-Hodgkin lymphoma has a long latency period, so new diagnoses among past Roundup users will keep arriving for a generation. For the future claimants themselves, the bargain is far less clear. A person who is healthy today has no way to evaluate whether $40,000 — the approximate cap for residential users under the deal — is adequate compensation for a cancer they have not yet developed. By comparison, individual Roundup trial verdicts have at times reached into the millions, which is precisely why objectors describe the class payouts as a fraction of what litigated claims have been worth. Federal MDL Judge Vince Chhabria, who has overseen Roundup litigation in federal court for years, has voiced concern about exactly this problem: whether a Missouri state-court deal can legally bind Roundup users outside Missouri and people who have not yet developed cancer at all.
What the Objectors Say Is Wrong With the Deal
The objections filed in May 2026 attack the settlement on several fronts. The Keller Postman and Frazer filing, on behalf of 10 victims from nine states, argues the deal violates constitutional due process — the principle that a court cannot take away a person’s legal claim without adequate notice and a meaningful opportunity to be heard. Their filing contends the opt-out process is “comically difficult,” a serious charge because the right to opt out is the primary safeguard that makes class settlements constitutional in the first place. If leaving the class is impractical, absent class members are effectively trapped in a deal negotiated without them.
The broader objection pool — more than 100 class members and about a dozen health care plans — raised additional problems: inadequate notice to the class, jurisdictional defects, inconsistent treatment of similarly situated class members, and the size of the attorney fee request, which stands at $675 million. Objecting victims have described the compensation levels as “unconscionably low,” particularly measured against the severity of a non-Hodgkin lymphoma diagnosis. There is an important limitation for anyone watching this case: objecting is not the same as escaping the deal. Class members who wanted to preserve their right to sue individually had to opt out by June 4, 2026. Those who missed that deadline and whose objections are overruled will generally be bound by whatever the Missouri court ultimately approves, subject to appeal.
The Jurisdictional Fight — Why This Case Bounced Between Courts
One of the more unusual procedural episodes in this litigation came when objectors attempted to move the case out of Missouri state court entirely. Non-defendant objectors removed King v. Monsanto to federal court, arguing a nationwide settlement of this magnitude belonged before a federal judge. On June 17, 2026, U.S. District Judge Henry Autrey rejected that maneuver and remanded the case to Missouri state court, ruling that objectors who are not defendants lack the authority to remove a case to federal court.
The ruling was a procedural win for Monsanto, which had chosen the Missouri forum. The forum matters more than it might appear. The federal Roundup multidistrict litigation is overseen by Judge Chhabria in California, who has publicly questioned whether the Missouri deal can bind out-of-state users and future claimants. Keeping the settlement in a Missouri state courtroom keeps it away from that skepticism. Objectors, in turn, worry that a single state trial court is being asked to approve a nationwide release of claims — including claims held by people in states with very different tort law — which is part of the jurisdictional objection now before the court.
What Class Members Can Do — Opting Out Versus Staying In
For Roundup users weighing their position, the settlement presented a classic tradeoff. Staying in the class means accepting the settlement’s compensation structure — with residential users capped at roughly $40,000 — in exchange for certainty and no litigation burden. Opting out preserves the right to sue Bayer individually, where verdicts have historically been far larger, but requires finding counsel, proving causation, and waiting out years of litigation with no guaranteed recovery. That is the tradeoff the objectors say was never fairly presented, given what they call a “comically difficult” opt-out mechanism.
The opt-out window closed on June 4, 2026. Class members who acted by that date are outside the deal regardless of what happens at the fairness hearing. Everyone else is now effectively waiting on the Missouri court: the final fairness hearing, originally scheduled for July 9, 2026, was rescheduled to August 19, 2026, and final approval remains pending. Anyone who filed a timely objection retains the ability to press those arguments at the hearing and, if approval is granted, potentially on appeal — which is how landmark futures settlements, including the asbestos deals struck down by the Supreme Court in the 1990s, were ultimately unwound.
The Futures Problem — Why Courts Have Struck Down Deals Like This Before
The legal vulnerability at the heart of this settlement has a history. In Amchem Products v. Windsor and Ortiz v. Fibreboard, the U.S. Supreme Court invalidated asbestos class settlements that tried to resolve the claims of people who had been exposed but not yet injured.
The Court’s reasoning is directly relevant here: future claimants cannot meaningfully evaluate a settlement, may not even know they are class members, and their interests conflict with those of current claimants who want money paid out now. Objectors to the Roundup deal invoke exactly this line of authority, noting that the King v. Monsanto futures subclass could reach people “not yet conceived.” The warning for class members is that even a court-approved settlement of this type carries real risk of being overturned years later. If the Missouri court grants final approval on or after the August 19, 2026 hearing, appellate review of the due process and jurisdictional objections could stretch on for years, leaving both current claimants awaiting payment and future claimants’ rights in limbo. A settlement fund scheduled to pay out over 17 to 21 years compounds that uncertainty — claimants are betting on Bayer’s willingness and ability to fund the deal across two decades.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
The $675 Million Attorney Fee Request
Among the specific objections drawing scrutiny is the request for $675 million in attorney fees for class counsel — a figure objectors contrast with the roughly $40,000 cap facing residential users. Health care plans and individual class members alike flagged the fee request in their filings, arguing it signals a deal negotiated with counsel’s interests, not class members’, at the center.
That is the substance behind the “sweetheart deal” label in the Keller Postman and Frazer objection: the claim that Bayer bought global peace at a discount while class counsel secured a nine-figure fee. Fee objections are among the most common grounds courts use to modify settlements without rejecting them outright, so even if the Missouri court approves the overall structure in August, the $675 million figure could be reduced independently.
Where the Glyphosate Litigation Stands Beyond This Settlement
The King v. Monsanto class deal does not exist in a vacuum.
Thousands of Roundup cases remain pending in the federal MDL before Judge Chhabria and in state courts nationwide, and claimants who opted out by the June 4, 2026 deadline will continue litigating on those tracks. Bayer has simultaneously pursued legislative and regulatory strategies around glyphosate labeling, and it continues to sell Roundup — meaning new exposures, and potentially new claims, accrue even as the company seeks to close the book on future liability through the futures subclass now under fire in Missouri.
Frequently Asked Questions
How much is the proposed Bayer Roundup class settlement?
Bayer/Monsanto proposed $7.25 billion to resolve existing and future non-Hodgkin lymphoma claims tied to glyphosate, filed as King v. Monsanto in Missouri state court.
Who objected to the settlement?
Keller Postman LLC and Frazer PLC filed objections for 10 victims from nine states, joined by more than 100 class members and about a dozen health care plans.
What is the main objection to the deal?
Objectors say binding future cancer victims — people not yet diagnosed — violates constitutional due process, and that the opt-out process is “comically difficult.”
What was the opt-out deadline?
Class members had until June 4, 2026 to opt out and preserve their right to sue individually.
When will the settlement be approved or rejected?
The final fairness hearing was rescheduled from July 9, 2026 to August 19, 2026, so final approval remains pending.
Why is the case in Missouri state court instead of federal court?
On June 17, 2026, Judge Henry Autrey remanded the case to Missouri state court, ruling non-defendant objectors could not remove it to federal court.
You Might Also Like
- NextEra Nuclear Plant Wage Class Action Settlement Resolves Claims Worker Pay Was Suppressed
- Equity Residential Rent Antitrust Settlement Resolves Claims Apartment Prices Were Inflated
- Wiley Rein Data Breach Class Action Claims Hackers Stole Sensitive Client Information